Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 39 studies | 44% ± 19% | |
classical monocyte | 27 studies | 51% ± 15% | |
non-classical monocyte | 26 studies | 62% ± 16% | |
monocyte | 23 studies | 38% ± 18% | |
myeloid cell | 15 studies | 37% ± 17% | |
neutrophil | 13 studies | 52% ± 16% | |
ciliated cell | 11 studies | 26% ± 9% | |
alveolar macrophage | 8 studies | 41% ± 14% | |
dendritic cell | 6 studies | 39% ± 16% | |
mononuclear phagocyte | 6 studies | 37% ± 14% | |
conventional dendritic cell | 6 studies | 32% ± 10% | |
intermediate monocyte | 6 studies | 49% ± 23% | |
leukocyte | 4 studies | 26% ± 4% | |
tissue-resident macrophage | 3 studies | 47% ± 7% | |
inflammatory macrophage | 3 studies | 27% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 5456.39 | 578 / 578 | 97% | 27.36 | 1119 / 1155 |
kidney | 73% | 961.40 | 65 / 89 | 97% | 26.04 | 872 / 901 |
breast | 70% | 970.34 | 320 / 459 | 97% | 17.40 | 1079 / 1118 |
intestine | 76% | 906.66 | 735 / 966 | 85% | 16.16 | 449 / 527 |
uterus | 64% | 676.80 | 109 / 170 | 88% | 14.06 | 406 / 459 |
bladder | 76% | 757.95 | 16 / 21 | 75% | 14.63 | 380 / 504 |
adrenal gland | 86% | 1125.59 | 223 / 258 | 62% | 11.20 | 142 / 230 |
ovary | 49% | 485.92 | 89 / 180 | 91% | 17.58 | 393 / 430 |
liver | 70% | 1102.51 | 158 / 226 | 68% | 7.72 | 276 / 406 |
stomach | 45% | 642.43 | 163 / 359 | 90% | 21.15 | 257 / 286 |
prostate | 59% | 575.48 | 144 / 245 | 73% | 7.31 | 368 / 502 |
esophagus | 35% | 370.05 | 504 / 1445 | 91% | 18.48 | 167 / 183 |
pancreas | 20% | 155.33 | 64 / 328 | 97% | 28.70 | 172 / 178 |
thymus | 40% | 317.15 | 260 / 653 | 74% | 8.59 | 450 / 605 |
spleen | 100% | 4696.54 | 240 / 241 | 0% | 0 | 0 / 0 |
brain | 18% | 215.86 | 463 / 2642 | 79% | 20.35 | 555 / 705 |
adipose | 94% | 3035.16 | 1127 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 30.03 | 27 / 29 |
blood vessel | 93% | 2140.82 | 1241 / 1335 | 0% | 0 | 0 / 0 |
skin | 15% | 163.68 | 270 / 1809 | 76% | 12.06 | 361 / 472 |
tonsil | 0% | 0 | 0 / 0 | 89% | 11.99 | 40 / 45 |
peripheral blood | 82% | 28270.64 | 763 / 929 | 0% | 0 | 0 / 0 |
heart | 50% | 632.35 | 432 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 11% | 0.64 | 9 / 80 |
muscle | 2% | 11.44 | 13 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006954 | Biological process | inflammatory response |
GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
GO_0001774 | Biological process | microglial cell activation |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0048143 | Biological process | astrocyte activation |
GO_0007165 | Biological process | signal transduction |
GO_0030593 | Biological process | neutrophil chemotaxis |
GO_0006935 | Biological process | chemotaxis |
GO_0006968 | Biological process | cellular defense response |
GO_0038178 | Biological process | complement component C5a signaling pathway |
GO_0010759 | Biological process | positive regulation of macrophage chemotaxis |
GO_0032494 | Biological process | response to peptidoglycan |
GO_0097242 | Biological process | amyloid-beta clearance |
GO_0006955 | Biological process | immune response |
GO_0050679 | Biological process | positive regulation of epithelial cell proliferation |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
GO_1902947 | Biological process | regulation of tau-protein kinase activity |
GO_0007606 | Biological process | sensory perception of chemical stimulus |
GO_0010575 | Biological process | positive regulation of vascular endothelial growth factor production |
GO_0042789 | Biological process | mRNA transcription by RNA polymerase II |
GO_0090023 | Biological process | positive regulation of neutrophil chemotaxis |
GO_0050890 | Biological process | cognition |
GO_0099172 | Biological process | presynapse organization |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0002430 | Biological process | complement receptor mediated signaling pathway |
GO_0030667 | Cellular component | secretory granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0045177 | Cellular component | apical part of cell |
GO_0016323 | Cellular component | basolateral plasma membrane |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0004878 | Molecular function | complement component C5a receptor activity |
Gene name | C5AR1 |
Protein name | Complement C5a receptor 1 C5a anaphylatoxin chemotactic receptor 1 (C5a anaphylatoxin chemotactic receptor) (C5a-R) (C5aR) (CD antigen CD88) |
Synonyms | C5R1 C5AR |
Description | FUNCTION: Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a . The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N-terminus, and a second site in the transmembrane region which activates downstream signaling events . Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production . . |
Accessions | ENST00000355085.4 ENST00000594787.1 M0QZK7 P21730 |